Senti Biosciences, Inc.

NASDAQ
SNTI
paper.types.company
Rentabilité sur six mois: +48.61%
Rendement en dividendes: 0%
Secteur: Healthcare

3.21 $

-0.1 $ -3.02%
0.237 $
10 $

paper.min_max_per_year

Calendrier des promotions Senti Biosciences, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Senti Biosciences, Inc.

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.

plus de détails
The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2022-06-09
ISIN
US81726A1007
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 9.51 1
P/BV 0.3641 10
P/E 0 0
Efficacité
Nom Signification Grade
ROA -59.47 0
ROE -106.19 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.6122 10
Debt/Ratio 0.3152 10
Debt/Equity 0.7857 9
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 2912.94 10
Rentabilité Ebitda, % 186.62 10
Rentabilité EPS, % 1244.77 10
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 3.31 $ 0 $ 0 $ -3.02 % 0 % 0 %
common.calendar.number_days.7d 3.05 $ 0 $ 0 $ 5.25 % 0 % 0 %
common.calendar.number_days.30d 3.17 $ 3.05 $ 3.31 $ 1.26 % 0 % 0 %
common.calendar.number_days.90d 3.66 $ 2.88 $ 5 $ -12.3 % 0 % 0 %
common.calendar.number_days.180d 2.16 $ 2.86 $ 5.59 $ 48.61 % 0 % 0 %
common.calendar.number_days.1y 0.313 $ 0.237 $ 10 $ 925.56 % 0 % 0 %
common.calendar.number_days.3y 9.94 $ 0.237 $ 10 $ -67.71 % 0 % 0 %
common.calendar.number_days.5y 0 $ 0.237 $ 10.24 $ 0 % 0 % 0 %
common.calendar.number_days.10y 0 $ 0.237 $ 10.24 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 4 $ 2.86 $ 5 $ -19.75 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Timothy K. Lu M.D., Ph.D. Co-Founder, CEO & Director 868.57k 1981 (44 année)
Dr. James J. Collins Ph.D. Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director 58.5k 1966 (59 années)
Dr. Kanya Rajangam M.D., Ph.D. President, Head of Research & Development and Chief Medical Officer 689.99k 1974 (51 année)
Dr. Wilson Wong Ph.D. Scientific Co-Founder & Member of Scientific Advisory Board N/A
Ms. Yvonne Li M.B.A. Interim CFO, Treasurer & Principal Accounting Officer 1960 (65 années)
Mr. Thomas P. Chung Vice President of Strategic Finance & Corporate Development
Ms. Dee Olomajeye Dragon Vice President of People Strategy & Culture

Informations sur l'entreprise

Adresse: United States, South San Francisco. CA, 2 Corporate Drive - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.sentibio.com